Similar articles

• Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.

  Galli M, Balotta C, Meroni L, Colombo MC, Papagno L, Bagnarelli P, Testa L, Varchetta S, Colombo L, Moroni M, d'Arminio Monforte A, Clerici M, Clementi M. Galli M, et al. AIDS. 1998 Dec 24;12(18):2500-2. AIDS. 1998. PMID: 9875591 No abstract available.
• Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.

  Clark NM, Dieng Sarr A, Sankalé JL, Kanki PJ, Kazanjian P, Winfield R, Markovitz DM. Clark NM, et al. AIDS. 1998 Dec 24;12(18):2506-7. AIDS. 1998. PMID: 9875594 No abstract available.
• Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants.

  Van der Linden D, Hainaut M, Goetghebuer T, Haelterman E, Schmitz V, Maes P, Peltier A, Levy J. Van der Linden D, et al. Pediatr Infect Dis J. 2007 Apr;26(4):359-61. doi: 10.1097/01.inf.0000258626.34984.eb. Pediatr Infect Dis J. 2007. PMID: 17414406 Clinical Trial.
• Salvage therapy for patients failing their current antiretroviral regimen.

  Albrecht MA. Albrecht MA. AIDS Clin Rev. 2000-2001:139-91. AIDS Clin Rev. 2000. PMID: 10999220 Review. No abstract available.
• Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).

  Pujari S, Patel A, Joshi SR, Gangakhedkar R, Kumarasamy N, Gupta SB; Expert Panel 2008. Pujari S, et al. J Assoc Physicians India. 2008 May;56:339-48, 353-71. J Assoc Physicians India. 2008. PMID: 18700643 Review. No abstract available.